Outcome
Type |
Measure |
Description |
Time frame |
Safety issue |
Primary |
Adverse pregnancy outcome |
Composite of foetal loss (spontaneous abortion or stillbirth), or singleton live births born small-for-gestational age (SGA), or with low birthweight (LBW), or preterm (PT) (SGA-LBW-PT), or subsequent neonatal death by day 28. |
8 months |
|
Secondary |
Composite of foetal loss and neonatal mortality |
Composite of foetal loss (spontaneous abortion or stillbirth) and neonatal mortality |
8 months |
|
Secondary |
SGA-LBW-PT composite |
Composite of small for gestational age, low birth weight or preterm birth |
6 months |
|
Secondary |
SGA |
Small for gestational age using the new INTERGROWTH population reference's 10th percentile |
6 months |
|
Secondary |
LBW |
Low birth weight defined as a corrected birth weight below 2.5 kg |
6 months |
|
Secondary |
PT |
Preterm birth defined as birth at a gestational age above 28 weeks but less than 37 completed weeks |
6 months |
|
Secondary |
Neonatal length and stunting |
Neonatal length and stunting |
8 months |
|
Secondary |
Clinical malaria during pregnancy |
Incidence of clinical malaria during pregnancy |
6 months from randomisation |
|
Secondary |
Malaria infection during pregnancy detected by microscopy and PCR |
Prevalence and incidence of peripheral maternal (blood) malaria infection during pregnancy by microscopy and PCR |
6 months from randomisation |
|
Secondary |
Composite placental malaria detected by microscopy, by molecular methods or by histology |
Prevalence of placental malaria by microscopy, PCR and placental histology |
6 months from randomisation |
|
Secondary |
Placental malaria detected by microscopy |
Prevalence of placental malaria detected in maternal placental blood by microscopy |
6 months from randomisation |
|
Secondary |
Placental malaria detected by molecular methods (PCR) |
Prevalence of placental malaria detected in maternal placental blood by PCR |
6 months from randomisation |
|
Secondary |
Placental malaria detected by histology |
Prevalence of placental malaria detected in full placental section by histology |
6 months from randomisation |
|
Secondary |
Maternal nutritional status |
Changes in maternal nutritional status by MUAC and BMI. |
6 months from randomisation |
|
Secondary |
Maternal anaemia during pregnancy and delivery |
Prevalence and incidence of maternal anaemia (Hb < 11g/dl) at enrolment, last antenatal visit and delivery |
6 months from randomisation |
|
Secondary |
Congenital anaemia |
Prevalence of anaemia (Hb < 13g/dl) from newborn cord blood |
6 months from randomisation |
|
Secondary |
Congenital malaria infection |
Prevalence of malaria infection by microscopy or PCR from newborn cord blood |
6 months from randomisation |
|
Secondary |
QTc-prolongation |
QTcF-prolongation of more than 60ms between baseline DTcF prior to first dose of DP (+/- AZ) on day 0 and repeat QTcF 4 - 6 hrs after administration of 3rd dose of DP(+/- AZ) on day 2, or QTcF > 480ms, 4 - 6 hours after on day 2 treatment administration. Only on the DP containing arms. |
6 months from randomisation |
|
Secondary |
Congenital malformations |
Any visible external congenital abnormality on surface examination |
6 months from randomisation |
|
Secondary |
Maternal mortality |
The death of a woman while pregnant or within 42 days of termination of pregnancy, irrespective of the duration and site of the pregnancy, from any cause related to or aggravated by the pregnancy or its management but not from accidental or incidental causes. |
8 months from randomisation |
|
Secondary |
Other SAEs and AEs |
Incidence of AEs and SAEs |
8 months from randomisation |
|
Secondary |
(History of) vomiting study drug |
Prevalence and incidence of vomiting investigational product (IP) twice at the same IP administration visit |
6 months from randomisation |
|
Secondary |
Dizziness |
Prevalence of dizziness after a course of IP |
6 months from randomisation |
|
Secondary |
Gastrointestinal complaints |
Prevalence of gastrointestinal complaints after a course of IP |
6 months from randomisation |
|
Secondary |
Molecular markers of drug resistance in Plasmodium falciparum infections during pregnancy and delivery |
Prevalence and incidence of SP and artemisinin resistance markers from infection isolates after enrollment and at delivery |
6 months from randomisation |
|
Secondary |
Presence of STIs/RTIs prior to delivery (syphilis, gonorrhoea, Chlamydia trachomatis, Trichomonas vaginalis, and bacterial vaginosis) |
Prevalence and incidence of STIs/RTIs (syphilis, gonorrhoea, Chlamydia trachomatis, Trichomonas vaginalis, and bacterial vaginosis) at randomization and last antenatal visit prior to delivery |
6 months from randomisation |
|
Secondary |
Changes in macrolide resistance in Pneumococcus detected in maternal nasopharyngeal samples |
Prevalence and incidence of carriage of macrolide resistant pneumococcus at randomization and delivery |
6 months from randomisation |
|
Secondary |
Changes in the colony composition of maternal vaginal microbiota, and intestinal microbiota of mother and infant. |
Changes in maternal reproductive tract and gut microbiota from randomisation to last antenatal visit prior to delivery, and neonatal gut microbiota |
6 months from randomisation |
|